Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols and unique delivery systems. Mydecine has exclusive access to a full cGMP-certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, Colorado, to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.
To learn more about the company, visit www.mydecine.com
To view IBN’s virtual coverage of Benzinga’s upcoming Cannabis Capital Conference, visit https://ibn.fm/BenzingaCannabisFeb2021
For registration information and further details on this week’s conference, visit https://www.benzinga.com/events/cannabis/virtual/
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured session.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
